Aprea Therapeutics
APRE
19 hedge funds and large institutions have $2.78M invested in Aprea Therapeutics in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 1 reducing their positions, and 2 closing their positions.
4,868% more capital inflows, than outflows
Capital inflows: $127K | Capital outflows: $2.56K
600% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 1
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
6% more funds holding
Funds holding: 18 → 19 (+1)
0.9% more ownership
Funds ownership: 22.74% → 23.64% (+0.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$87.9K |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$16K |
| 3 |
Worth Venture Partners
Fort Lee,
New Jersey
|
+$8.57K |
| 4 |
Tower Research Capital (TRC)
New York
|
+$6.89K |
| 5 |
MB, Levis & Associates
Center Valley,
Pennsylvania
|
+$3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$2.5K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$44 |
| 3 |
Quent Capital
New York
|
-$13 |
APRE Hedge Fund Activity: Q2 2023 in Review
19 of the 6,389 institutional investors tracked by Wall St. Rank reported a position in Aprea Therapeutics (APRE) for Q2 2023, worth a combined $2.78M — down 26% from $3.77M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new APRE positions and 2 closed out — a net gain of 1 holder — while 7 added to existing stakes and 1 trimmed.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $87.9K. The largest seller was UBS Group, cutting an estimated $2.5K.
- 19 institutional investors held Aprea Therapeutics (APRE) as of Q2 2023, up from 18 in Q1 2023.
- Funds reported $2.78M of Aprea Therapeutics stock for Q2 2023, down 26% quarter-over-quarter.
- 3 funds opened new Aprea Therapeutics positions in Q2 2023 and 2 closed out, a net change of +1 holder.
- The largest Aprea Therapeutics buyer in Q2 2023 was Geode Capital Management, an estimated $87.9K added.
- The largest Aprea Therapeutics seller in Q2 2023 was UBS Group, an estimated $2.5K sold.
Based on aggregated 13F filings for Q2 2023.